loader image
Saturday, December 20, 2025
84.8 F
McAllen
- Advertisement -

AI Tool Detects Parkinson’s Up To 15 Years Early With 96% Accuracy

Translate to Spanish or other 102 languages!

Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes
Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes

Medical News Today

- Advertisement -
  • Researchers developed an AI tool to predict Parkinson’s disease from blood samples. 
  • The tool can predict Parkinson’s 15 years before symptom onset with 96% accuracy. 
  • The underlying technology could possibly be adapted for diagnosing other conditions. 

Parkinson’s disease is a neurodegenerative condition characterizedTrusted Source by unintended movements such as shaking, stiffness, and difficulty balancing. It is caused by the loss of nerve cells in the brain, leading to reduced levels of dopamine, which plays a key role in movement.

To read the full story on Medical News Today Follow the link below: 

https://www.medicalnewstoday.com/articles/ai-tool-detects-parkinsons-up-to-15-years-early-with-96-accuracy?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-05-18&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.

Early Findings Show Breast Cancer Vaccine Produces Immune Response

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine. 
- Advertisement -
×